Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) – Wedbush raised its second quarter 2022 EPS estimates for Biohaven Pharmaceutical in a note to investors on Tuesday, January 25. Wedbush analyst L. Chico now expects the company to post earnings per share of ($0.77) for the quarter, up from his previous forecast of ($0.93). Wedbush also released estimates of Biohaven Pharmaceutical’s Q3 2022 earnings at ($0.51) EPS, Q4 2022 earnings at ($0.28) EPS and fiscal year 2022 earnings at ($2.70) ) EPS.
BHVN has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $160.00 price target on Biohaven Pharmaceutical shares in a research report on Friday, January 7. Goldman Sachs Group raised its price target on Biohaven Pharmaceutical from $151.00 to $170.00 and gave the stock a “buy” rating in a Wednesday, October 6 research report. Piper Sandler raised her price target on Biohaven Pharmaceutical from $140.00 to $156.00 and gave the stock an “overweight” rating in a Tuesday, October 5 research report. SVB Leerink reissued a “buy” rating on Biohaven Pharmaceutical shares in a research report on Thursday, October 7. Finally, Mizuho raised its price target on Biohaven Pharmaceutical from $135.00 to $144.00 and gave the company a “buy” rating in a Thursday, November 18 research report. Three equity research analysts gave the stock a hold rating and nine gave the company a buy rating. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $147.55.
Biohaven Pharmaceutical Stock opened at $126.08 on Thursday. The stock’s 50-day simple moving average is $120.00 and its two-hundred-day simple moving average is $126.55. Biohaven Pharmaceutical has a fifty-two week low of $62.57 and a fifty-two week high of $151.51. The stock has a market capitalization of $8.26 billion, a price-earnings ratio of -9.21 and a beta of 1.04. Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings data on Monday, November 8. The company reported ($2.63) earnings per share for the quarter, missing Thomson Reuters consensus estimate of ($2.40) by ($0.23). The company posted revenue of $135.74 million in the quarter, versus analyst estimates of $128.40 million. The company’s quarterly revenue increased 668.5% year over year. During the same quarter last year, the firm posted ($3.27) earnings per share.
Major investors have recently been buying and selling shares of the company. Russell Investments Group Ltd. increased its stake in shares of Biohaven Pharmaceutical by 14.5% in Q3. Russell Investments Group Ltd. now owns 61,683 shares of the company worth $8,567,000 after purchasing an additional 7,791 shares last quarter. Ensign Peak Advisors Inc increased its stake in shares of Biohaven Pharmaceutical by 20.7% in Q2. Ensign Peak Advisors Inc now owns 79,461 shares of the company worth $7,714,000 after purchasing an additional 13,653 shares in the last quarter. Montag A & Associates Inc. bought a new position in Biohaven Pharmaceutical in Q3 worth $96,000. Virtu Financial LLC bought a new position in Biohaven Pharmaceutical in Q2 worth $467,000. Finally, Teacher Retirement System of Texas increased its stake in Biohaven Pharmaceutical by 40.3% in the third quarter. Teacher Retirement System of Texas now owns 9,254 shares of the company worth $1,285,000 after purchasing an additional 2,660 shares during the period. Hedge funds and other institutional investors hold 89.17% of the company’s shares.
In other news, Insider Elysee Stock sold 21,919 shares of the company in a trade on Wednesday, December 15. The stock was sold at an average price of $105.49, for a total value of $2,312,235.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available via the SEC website. Additionally, director John W. Childs acquired 5,000 shares of Biohaven Pharmaceutical in a transaction dated Wednesday, November 10. The stock was purchased at an average price of $122.87 per share, with a total value of $614,350.00. Disclosure of this purchase can be found here. During the last quarter, insiders sold 142,474 shares of the company valued at $15,904,399. Insiders of the company hold 15.20% of the shares of the company.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company, dedicated to the research and development of late-stage product candidates targeting neurological diseases, including rare diseases. It is focused on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-linked peptide receptor antagonists and glutamate modulators.
Recommended Story: What is the G-20?
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Biohaven Pharmaceutical right now?
Before you consider Biohaven Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Biohaven Pharmaceutical didn’t make the list.
Although Biohaven Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here